Dissecting the fatigue experience: A scoping review of fatigue definitions, dimensions, and measures in non-oncologic medical conditions

Brain Behavior & Immunity - Health, Journal Year: 2021, Volume and Issue: 15, P. 100266 - 100266

Published: May 21, 2021

Fatigue is a prevalent and potentially debilitating symptom that impacts the health-related quality-of-life of individuals diagnosed with acute chronic medical conditions. Yet, its etiologic mechanism not fully understood. Additionally, assessment determination clinical meaning fatigue multidimensionality may vary by condition. A scoping literature review was conducted to investigate how defined measured, including dimensions, in non-oncologic The PubMed database searched using keywords. Overall, 8376 articles were screened at title/abstract levels, where 293 chosen for full-text mentioned or included measures. full text excluded 246 did assess least one dimension validated questionnaires tests. final set 47 articles. Physical most assessed Multidimensional Inventory widely used questionnaire this review. This limited only English-language publications as sole search. affirms multidimensional construct, agnostic condition, individual dimensions can be measured Future research should focus on expanding repertoire measures specific dimensions.

Language: Английский

---

Fatigue in patients with myasthenia gravis. A systematic review of the literature

Neuromuscular Disorders, Journal Year: 2020, Volume and Issue: 30(8), P. 631 - 639

Published: July 1, 2020

Myasthenia Gravis (MG) is a chronic autoimmune disease affecting the neuromuscular junction. Although hallmark of MG muscle fatigability due to dysfunction junction (peripheral fatigue), large number patients also report symptoms central fatigue, defined as an experienced lack energy, physically and/or mentally. We systematically reviewed literature on all aspects fatigue in MG. Results were categorized 5 domains: prevalence, diagnosis, pathophysiology, treatment or impact. The prevalence patient-reported varies between 42 and 82%, which significantly higher than control subjects. Fatigue severity usually assessed with standardized questionnaires, but choice questionnaire widely studies. pathophysiology unknown, it strongly associated depressive symptoms, female gender severity. highly prevalent ocular remission, suggesting multifactorial origin. Fatigued have lower quality life. Pharmacological improvement promising results been found physical psychological training programs. symptom severe negative impact Physicians treating should be aware this symptom, may treatable

Language: Английский

---

Fatigue in patients with myasthenia gravis

Journal of Neurology, Journal Year: 2018, Volume and Issue: 265(10), P. 2312 - 2321

Published: Aug. 11, 2018

Language: Английский

---

The humanistic burden of myasthenia gravis: A systematic literature review

Journal of the Neurological Sciences, Journal Year: 2022, Volume and Issue: 437, P. 120268 - 120268

Published: April 21, 2022

While the clinical manifestations of myasthenia gravis (MG) are well understood, its humanistic impact is not. The objective this systematic literature review (SLR) was to provide a comprehensive understanding burden MG with regards psychological symptoms and health-related quality life (HRQoL) according patients caregivers.A search conducted on December 27, 2019, in MEDLINE Embase identify English-language studies that were published from January 1, 2009-December 2019 presented relevant information among adults their caregivers. Title/abstract full-text screening performed by two investigators, any discrepancies resolved third investigator.Sixty-seven publications included SLR. Compared general population, experienced worse HRQoL. Studies reporting MG, including depression, anxiety, fatigue, sleep, heterogeneous terms scales instruments used assess patients, as patient populations themselves. However, those more severe hospitalization days had depression fatigue sleep improved disease remission and/or improvement. Scores for females compared males where evaluated, HRQoL scores generally following treatment.While demonstrates associated get better improvement remission, additional options efficacious therapy adequately address disease-related also improve may contribute beneficial outcomes greater number MG.

Language: Английский

---

miR‐30e‐5p as predictor of generalization in ocular myasthenia gravis

Annals of Clinical and Translational Neurology, Journal Year: 2019, Volume and Issue: 6(2), P. 243 - 251

Published: Jan. 24, 2019

Abstract Objective To determine a predictive factor for the risk of conversion from ocular myasthenia gravis ( OMG ) to generalized MG GMG in prospective study. Methods RNA was isolated serum samples and detection micro (mi expression analyzed with qPCR . In discovery set, 179 human mi s were assayed profiling five patients four age‐ gender‐matched healthy controls. Based on specific accumulation pattern 19 addition previously found elevated ; miR‐150‐5p miR‐30e‐5p), 21 subsequently validation cohort 83 (82 immunosuppression treatment naive; 49 male) within 3 months diagnosis at follow‐up visit (median duration 28 first visit). Results Thirteen 14.8 ± 12.0 after majority (85%) belonged late onset group. Two significantly higher secondary SGMG compared : miR‐30e‐5p (9.1 0.5 vs. 6.3 0.9; P < 0.0001) (7.4 1.1 6.4 1.1; = 0.01). The sensitivity differentiating 96% all 100% patients. Interpretation This is study describe potential associated generalization Raised levels (>8) initial presentation symptoms, give cut‐off subsequent 96–100%.

Language: Английский

---

Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa

BMC Neurology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Feb. 10, 2024

Abstract Background Myasthenia gravis (MG) is a rare autoimmune disease characterised by muscle weakness, and progression from ocular (oMG) to generalised (gMG) symptoms results in substantial negative impact on quality of life (QoL). This systematic review aimed provide an overview the patient burden experienced people living with gMG. Methods Electronic database searches (conducted March 2022), supplemented interrogation grey literature, were conducted identify studies reporting outcomes patients gMG Europe, Middle East Africa. Results synthesised narratively due heterogeneity across trials. In total, 39 publications (representing 38 unique studies) identified as relevant for inclusion review, consisting 37 formal patient-reported outcome measures (PROMs), two describing alternative qualitative assessments experience. The included variety including generic disease-specific PROMs, well symptom-specific PROMs focusing key comorbidities depression, anxiety, fatigue sleep disturbance. findings showed some variation PROMs; however, general there was evidence worse QoL than healthy controls or oMG, trend worsening increasing MG severity. Conclusions highlights importance considering when developing assessing treatment management plans However, illustrates need further representative well-powered large cohorts administering consistent, validated questionnaires. Trial registration protocol this registered PROSPERO: CRD42022328444.

Language: Английский

---

Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: March 3, 2020

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies which attack receptors at the neuromuscular junction. One of main difficulties in predicting clinical course MG heterogeneity disease, where progression differs greatly depending on subgroup that patient classified into. subgroups are according to: age onset [early (EOMG; ≤ 50 years) versus late (LOMG; >50 years]; presence a thymoma (thymoma associated MG), antibody subtype [acetylcholine receptor seropositive (AChR+), muscle specific tyrosine kinase (MuSK+)], or against low-density lipoprotein receptor-related protein 4 (Lrp4) agrin as well subtypes (ocular generalized MG). The diagnostic tests for such titers, neurophysiological and objective fatigue score, do not necessarily reflect progression. Hence, there great need reliable biomarkers to follow individualized response therapy towards personalized medicine. In this regard, circulating microRNAs (miRNAs) have emerged promising potential due their accessibility body fluids unique profiles different diseases, including disorders. Several studies miRNAs revealed miRNA sera. AChR+ EOMG, miR-150-5p miR-21-5p most elevated miRNAs, with lower levels observed upon treatment immunosuppression thymectomy. LOMG, miR-150-5p, miR-30e-5p decrease accordance after immunosuppression. ocular MG, higher discriminate patients who will later generalize from those remaining ocular. contrast, MuSK+ let-7 family members elevated. Studies profile Lrp4 still lacking. This review summarizes present knowledge MG.

Language: Английский

---

A Physical and Psychological Approach to Managing Fatigue in Myasthenia Gravis: A Pilot Study

Journal of Neuromuscular Diseases, Journal Year: 2018, Volume and Issue: 5(3), P. 373 - 385

Published: June 5, 2018

BackgroundFatigue in myasthenia gravis (MG) is common and difficult to manage. Unlike myasthenic weakness it not amenable drug therapies.ObjectiveOur primary aim was investigate whether a combination of physical psychological therapy would help address symptoms fatigue MG patients, who have stable disease but residual problematic fatigue. Our secondary quantitate by applying different scores ascertain which be most relevant apply MG.MethodsWe recruited 10 patients with suffer from Nine these participated 10-week program that involved intervention. We quantified their using the modified impact scale (MFIS), visual analogue (VAFS) severity (FSS) at start study, various intervals during 3 months later.ResultsDuring program, there small improvement psychosocial subscale MFIS. There significant (p < 0.01) VAFS end program. No clear noted FSS. Three later, all declined baseline 50% had made some life-style changes.ConclusionsThis pilot utilized combined approach therapy, showed benefit improving MG. The unsustained. Because patient cohort, one cannot derive any firm conclusions larger study required this further.

Language: Английский

---

Lifestyle factors and disease-specific differences in subgroups of Swedish Myasthenia Gravis

Acta Neurologica Scandinavica, Journal Year: 2018, Volume and Issue: 138(6), P. 557 - 565

Published: Aug. 30, 2018

To evaluate disease-specific differences between Myasthenia Gravis (MG) subgroups and compare patterns of lifestyle MG patients population controls.All (n = 70) in Jönköping County, Sweden, were invited to answer a questionnaire, containing questions about data, lifestyle, comorbidity, mental fatigue. The clinically evaluated. Four hundred age- gender-matched controls the nondisease-specific part questionnaire. Disease-specific issues compared subgroups. Lifestyle-related factors concomitant conditions controls.Forty 188 participated study. In late-onset (LOMG; N 18) subgroup, male predominance was higher than previously reported. early-onset (EOMG; 17) time diagnosis longer, fatigue higher, bulbar weakness dominant symptom (65%). Compared their matched controls, LOMG more obese (OR 13.7, P 0.015), ate less fish 4.1, 0.012), tended smoke 0.086), be employed as manual laborers often 2.82, 0.083). Mental health problems sickness benefits common among regularly doing focused physical activity.It is important consider when tailoring management individual patients. There need for improved knowledge on how apply primary secondary prevention measures disorders without risk deterioration.

Language: Английский

---

Personality factors in patients with myasthenia gravis: A prospective study

Brain and Behavior, Journal Year: 2023, Volume and Issue: 13(11)

Published: Aug. 22, 2023

In myasthenia gravis (MG), depression and anxiety have frequently been reported as comorbidities. However, little is known about personality characteristics in MG patients. We aimed to characterise traits correlate them with disease severity course.The Big Five Inventory data questionnaire was used investigate 44 patients 45 healthy controls similar age gender. 28 patients, a caregiver also available for patient assessments limit bias associated social desirability patients' responses. Patients were assessed regard premorbid (before manifestation of MG) present condition. addition, scales (Hospital Anxiety Depression Scale Beck Inventory) applied.Compared controls, showed significantly higher levels neuroticism, whereas openness extraversion lower. Agreeableness conscientiousness did not differ between groups. Neuroticism influenced by such generalization weakness, presence thymoma, bulbar involvement well duration. correlated level neuroticism but scores.A profile increased lower may contribute considerably the perception severity. It be related frequent comorbidities depression. Although increased, this characteristic increase during course disease. The indicate that muscle weakness accompanied or even complicated psychological aspects. Therefore, behavioral intervention addition specific pharmacological therapy might particular value.

Language: Английский

---